Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment

References

• Grolleman JE, Díaz-Gay M, Franch-Expósito S, Castellví-Bel S, de Voer RM. Somatic mutational signatures in polyposis and colorectal cancer. Mol Aspects Med. 2019:69;62–72. doi:10.1016/j.mam.2019.05.002
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Shah MA, Renfro LA, Allegra CJ, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. J Clin Oncol. 2016;34(8):843–853. doi:10.1200/jco.2015.63.0558
   PubMed Web of Science ®Google Scholar
• Ge Y, Lei S, Cai B, et al. Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study. Int J Colorectal Dis. 2020;35(2):223–232. doi:10.1007/s00384-019-03434-8
   PubMed Web of Science ®Google Scholar
• McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal Cancer Chemotherapy: the Evolution of Treatment and New Approaches. Curr Med Chem. 2017;24(15):1537–1557. doi:10.2174/0929867324666170111152436
   PubMed Web of Science ®Google Scholar
• Tintelnot J, Stein A. Immunotherapy in colorectal cancer: available clinical evidence, challenges and novel approaches. World J Gastroenterol. 2019;25(29):3920–3928. doi:10.3748/wjg.v25.i29.3920
   PubMed Web of Science ®Google Scholar
• Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22. doi:10.1038/s41392-020-0116-z
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with kras wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–2401. doi:10.1001/jama.2017.7105
   PubMed Web of Science ®Google Scholar
• Wang F, Yuan X, Jia J, et al. Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: a multi-centre, Single-Arm, Prospective Study. Sci Rep. 2020;10(1):6058. doi:10.1038/s41598-020-62961-5
   PubMed Web of Science ®Google Scholar
• Yin L, Li J, Ma D, Li D, Sun Y. Angiogenesis in primary colorectal cancer and matched metastatic tissues: biological and clinical implications for anti-angiogenic therapies. Oncol Lett. 2020;19(5):3558–3566. doi:10.3892/ol.2020.11450
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019:11;7787–7803. doi:10.2147/cmar.s215533
   PubMed Web of Science ®Google Scholar
• Dhillon S. Regorafenib: a Review in Metastatic Colorectal Cancer. Drugs. 2018;78(11):1133–1144. doi:10.1007/s40265-018-0938-y
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang Q, Wang X, et al. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? Int J Colorectal Dis. 2020;35(2):295–306. doi:10.1007/s00384-019-03477-x
   PubMed Web of Science ®Google Scholar
• Chen X, Qiu T, Zhu Y, et al. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. Oncologist. 2019;24(7):883–e407. doi:10.1634/theoncologist.2019-0164
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/jco.2015.63.5995
   PubMed Web of Science ®Google Scholar
• Xu Y, Huang Z, Lu H, et al. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a Phase II, single-arm, multicentre, prospective study. Br J Cancer. 2019;121(8):640–646. doi:10.1038/s41416-019-0583-6
   PubMed Web of Science ®Google Scholar
• Wu F, Zhang S, Xiong A, et al. A Phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19(6):e831–e842. doi:10.1016/j.cllc.2018.06.002
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2015;16(6):619–629. doi:10.1016/s1470-2045(15)70156-7
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486–2496. doi:10.1001/jama.2018.7855
   PubMed Web of Science ®Google Scholar
• Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143(1):141–151. doi:10.1007/s10549-013-2793-6
   PubMed Web of Science ®Google Scholar
• Song ZZ, Zhao LF, Zuo J, et al. Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer in patients who progressed after standard therapy and analysis of the KDR Gene Polymorphism. Onco Targets Ther. 2020:13;603–613. doi:10.2147/ott.s222985
   PubMed Web of Science ®Google Scholar
• Yan Z, Gu YY, Hu XD, et al. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncol Lett. 2020;20(3):3035–3045. doi:10.3892/ol.2020.11857
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019:e27747. doi:10.1002/pbc.27747
   PubMed Web of Science ®Google Scholar
• Wu D, Nie J, Hu W, et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer. 2020. doi:10.1002/ijc.33161
   Web of Science ®Google Scholar
• Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev. 2017;7(7):Cd008398. doi:10.1002/14651858.CD008398.pub2
   PubMed Web of Science ®Google Scholar
• Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J. Current and advancing treatments for metastatic colorectal cancer. Expert Opin Biol Ther. 2016;16(1):93–110. doi:10.1517/14712598.2016.1108405
   PubMed Web of Science ®Google Scholar
• Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Adv Med Oncol. 2017;9(2):106–126. doi:10.1177/1758834016676703
   PubMed Web of Science ®Google Scholar
• Canavese M, Ngo DT, Maddern GJ, et al. Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. Int J Cancer. 2017;140(10):2183–2191. doi:10.1002/ijc.30567
   PubMed Web of Science ®Google Scholar
• Al-Shaheri FN, Al-Shami KM, Gamal EH, Mahasneh AA, Ayoub NM. Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes. Exp Mol Pathol. 2020:113;104364. doi:10.1016/j.yexmp.2019.104364
   PubMed Web of Science ®Google Scholar
• Su J, Dai B, Yuan W, et al. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study. Cancer Chemother Pharmacol. 2020;85(5):969–978. doi:10.1007/s00280-020-04069-1
   PubMed Web of Science ®Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in folfoxiri plus bevacizumab: analysis of the tribe trial. Cancers. 2020;12:7. doi:10.3390/cancers12071742
   Web of Science ®Google Scholar
• Tokunaga R, Cao S, Naseem M, et al. Prognostic effect of adenosine-related genetic variants in metastatic colorectal cancer treated with bevacizumab-based chemotherapy. Clin Colorectal Cancer. 2019;18(1):e8–e19. doi:10.1016/j.clcc.2018.09.003
   PubMed Web of Science ®Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Gene Polymorphisms in the CCL5/CCR5 pathway as a genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with regorafenib. Clin Colorectal Cancer. 2018;17(2):e395–e414. doi:10.1016/j.clcc.2018.02.010
   PubMed Web of Science ®Google Scholar
• Liao X, Li H, Liu Z, et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. Medicine. 2018;97(50):e13635. doi:10.1097/md.0000000000013635
   PubMed Web of Science ®Google Scholar
• Gou M, Si H, Zhang Y, et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018;8(1):4602. doi:10.1038/s41598-018-22302-z
   PubMed Web of Science ®Google Scholar
• Novakova-Jiresova A, Kopeckova K, Boublikova L, et al. Regorafenib for metastatic colorectal cancer: an analysis of a registry-based cohort of 555 patients. Cancer Manag Res. 2020:12;5365–5372. doi:10.2147/cmar.s255332
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for Colorectal Cancer: a Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst. 2019;111(11):1131–1141. doi:10.1093/jnci/djz093
   PubMedGoogle Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Rawla P, Barsouk A, Hadjinicolaou AV, Barsouk A. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Med Sci. 2019;7:8. doi:10.3390/medsci7080083
   Google Scholar
• Liu JY, Zhu BR, Wang YD, Sun X. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol. 2020;25(6):1195–1205. doi:10.1007/s10147-020-01644-7
   PubMed Web of Science ®Google Scholar
• Sullivan I, Riera P, Andres M, et al. Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis. 2019. doi:10.1007/s10456-019-09668-y
   PubMed Web of Science ®Google Scholar
• George DJ, Martini JF, Staehler M, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin Cancer Res. 2019;25(4):1165–1173. doi:10.1158/1078-0432.ccr-18-1724
   PubMed Web of Science ®Google Scholar
• Cho HD, Moon KD, Park KH, Lee YS, Seo KI. Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol. 2018:121;612–621. doi:10.1016/j.fct.2018.09.025
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu Q, Zuo Y, et al. Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer. 2017;17(1):875. doi:10.1186/s12885-017-3894-0
   PubMed Web of Science ®Google Scholar
• Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM. Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep. 2017;7(1):9602. doi:10.1038/s41598-017-08796-z
   PubMed Web of Science ®Google Scholar
• Ding M, Liu L, Hu C, et al. Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res. 2014;26(6):669–677. doi:10.3978/j.issn.1000-9604.2014.12.04
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang Y, Xue W, et al. The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer. Cancer Biol Ther. 2019;20(4):497–504. doi:10.1080/15384047.2018.1537575
   PubMed Web of Science ®Google Scholar
• Liang L, Wang L, Zhu P, et al. A pilot study of apatinib as third-line treatment in patients with heavily treated metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(3):e443–e449. doi:10.1016/j.clcc.2018.02.011
   PubMed Web of Science ®Google Scholar